Rapid Rx Quiz: Anticonvulsants

Mary L. Windle, PharmD

Disclosures

April 15, 2022

Ganaxolone is a GABAA receptor positive modulator. It binds specifically to GABAA receptors to enhance their inhibitory effects. It is indicated for seizures associated with cyclin-dependent kinase–like 5 deficiency disorder (CDD) in patients aged 2 years or older. CDD, a rare developmental epileptic encephalopathy caused by mutations in the CDKL5 gene, is largely a disease seen in pediatric and young adult patients.

Approval was based on the phase 3 MARIGOLD trial. Patients treated with ganaxolone (n = 49) showed a median 30.7% reduction in 28-day major motor seizure frequency, compared with a 6.9% reduction for those receiving placebo (n = 51) (P =.0036). In the open-label extension study, patients treated with ganaxolone for at least 12 months (n = 48) experienced a median 49.6% reduction in major motor seizure frequency.

Learn more about ganaxolone.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....